Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	10.24	10.07	9.49	10.16	7.31
Research & Development	23.68	19.83	22.98	22.33	19.34
Operating Expenses	33.92	29.91	32.48	32.49	26.65
Operating Income	-33.92	-29.91	-32.48	-32.49	-26.65
Interest Expense / Income	0.39	1.16	1.2	0.46	0
Other Expense / Income	-5.22	-1.88	0.28	-0.17	-0.58
Pretax Income	-29.1	-29.19	-33.96	-32.78	-26.07
Income Tax	-0.03	-0.04	-0.02	-0.02	-0.02
Net Income	-29.07	-29.15	-33.94	-32.76	-26.05
Preferred Dividends	0	0	0	0	0.7
Net Income Common	-29.07	-29.15	-33.94	-32.76	-26.75
Shares Outstanding (Basic)	99	65	23	18	12
Shares Outstanding (Diluted)	99	65	23	18	12
Shares Change	53.44%	182.56%	26.48%	53.88%	2581.79%
EPS (Basic)	-0.29	-0.45	-1.49	-1.81	-2.28
EPS (Diluted)	-0.29	-0.45	-1.49	-1.81	-2.28
Free Cash Flow	-31.85	-28.33	-28.95	-29.03	-23.1
Free Cash Flow Per Share	-0.32	-0.44	-1.27	-1.61	-1.97
EBITDA	-28.58	-27.98	-32.71	-32.27	-26.03
Depreciation & Amortization	0.12	0.04	0.05	0.05	0.04
EBIT	-28.71	-28.03	-32.76	-32.32	-26.07

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).